> Details

Ruef, Johannes; Störger, Hans; Schwarz, Franz; Haase,, Jürgen

Comparison of a polymer‐free rapamycin‐eluting stent (YUKON) with a polymer‐based paclitaxel‐eluting stent (TAXUS) in real‐world coronary artery lesions

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Comparison of a polymer‐free rapamycin‐eluting stent (YUKON) with a polymer‐based paclitaxel‐eluting stent (TAXUS) in real‐world coronary artery lesions
  • Contributor: Ruef, Johannes; Störger, Hans; Schwarz, Franz; Haase,, Jürgen
  • imprint: Wiley, 2008
  • Published in: Catheterization and Cardiovascular Interventions
  • Language: English
  • DOI: 10.1002/ccd.21326
  • ISSN: 1522-1946; 1522-726X
  • Keywords: Cardiology and Cardiovascular Medicine ; Radiology, Nuclear Medicine and imaging ; General Medicine
  • Origination:
  • Footnote:
  • Description: <jats:title>Abstract</jats:title><jats:p><jats:styled-content>Background</jats:styled-content>: In selected patient cohorts the polymer‐free rapamycin‐eluting YUKON stent (A) has demonstrated noninferiority compared with the polymer‐based paclitaxel‐eluting TAXUS stent (B). To test for equivalency in unselected real‐world patients with coronary lesions of various complexities, we retrospectively compared both stent designs. <jats:styled-content>Methods</jats:styled-content>: A total of 410 patients with symptomatic CAD were successfully treated with A (<jats:italic>n</jats:italic> = 205) or with B (<jats:italic>n</jats:italic> = 205). Baseline clinical characteristics, coronary lesion location, lesion length, and the number of stents implanted per lesion were equally distributed between the treatment groups. All patients underwent QCA‐analysis at baseline. Clinical follow‐up with assessment of MACE and noncardiac deaths was obtained at 30 days and 6 months. <jats:styled-content>Results</jats:styled-content>: Nominal stent diameter was 2.96 ± 0.38 mm in Group A vs. 3.05 ± 0.42 mm in Group B (<jats:italic>P</jats:italic> = 0.2); nominal length of stented segmentwas 22.97 ±13.0 mm vs. 23.63 ± 10.0 (<jats:italic>P</jats:italic> = 0.56). Analysis of MACE after 6 months resulted in one angiographically documented stent thrombosis causing MI in B (0.2%) vs. none in A. No other MI or cardiac deaths occurred in either group, while two noncardiac deaths in A (1.0%) were reported. Fifteen target lesion revascularizations (7.3%) were performed in A vs. 7 (3.4%) in B. Differences in study endpoints at 6 months did not reach statistical significance (<jats:italic>P</jats:italic> &gt; 0.05). <jats:styled-content>Conclusions</jats:styled-content>: Up to 6 months after PCI of real‐world coronary lesions, there were no statistically significant differences in MACE between patients treated with the polymer‐free rapamycin‐eluting YUKON stent and the polymer‐based paclitaxel‐eluting TAXUS stent. © 2008 Wiley‐Liss, Inc.</jats:p>